Literature DB >> 6148545

High-dose intravenous gammaglobulin for myasthenia gravis.

G Ippoliti1, V Cosi, G Piccolo, M Lombardi, R Mantegaz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6148545     DOI： 10.1016/s0140-6736(84)90729-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

Review 1.  Basic principles of intravenous immunoglobulin (IVIg) treatment.

Authors:  Martin Stangel; Refik Pul
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 2.  Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders.

Authors:  S A Schwartz
Journal:  J Clin Immunol       Date:  1990-03       Impact factor: 8.317

Review 3.  Intravenous immunoglobulin in neurological disease: a specialist review.

Authors:  C M Wiles; P Brown; H Chapel; R Guerrini; R A C Hughes; T D Martin; P McCrone; J Newsom-Davis; J Palace; J H Rees; M R Rose; N Scolding; A D B Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

4.  The clinical use of intravenous immunoglobulin in pediatrics.

Authors:  V Wahn
Journal:  Indian J Pediatr       Date:  1987 Sep-Oct       Impact factor: 1.967

5.  High-dose intravenous gamma-globulin therapy for myasthenia gravis.

Authors:  I B Ibars; J Ponseti; T Español; J Matias-Guiu; A Codina-Puiggros
Journal:  J Neurol       Date:  1987-06       Impact factor: 4.849

6.  Immediate effects of intravenous IgG administration on peripheral blood B and T cells and polymorphonuclear cells in patients with myasthenia gravis.

Authors:  L Cook; J F Howard; J D Folds
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

7.  High-dose intravenous immunoglobulin in myasthenia gravis.

Authors:  A Evoli; M T Palmisani; E Bartoccioni; L Padua; P Tonali
Journal:  Ital J Neurol Sci       Date:  1993-04

8.  Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies.

Authors:  Saiju Jacob; Yusuf A Rajabally
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

Review 9.  Current Treatment of Myasthenia Gravis.

Authors:  Mohammed K Alhaidar; Sumayyah Abumurad; Betty Soliven; Kourosh Rezania
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.